Online citations, reference lists, and bibliographies.

Conjunctivitis: A Systematic Review Of Diagnosis And Treatment.

A. Azari, N. Barney
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
IMPORTANCE Conjunctivitis is a common problem. OBJECTIVE To examine the diagnosis, management, and treatment of conjunctivitis, including various antibiotics and alternatives to antibiotic use in infectious conjunctivitis and use of antihistamines and mast cell stabilizers in allergic conjunctivitis. EVIDENCE REVIEW A search of the literature published through March 2013, using PubMed, the ISI Web of Knowledge database, and the Cochrane Library was performed. Eligible articles were selected after review of titles, abstracts, and references. FINDINGS Viral conjunctivitis is the most common overall cause of infectious conjunctivitis and usually does not require treatment; the signs and symptoms at presentation are variable. Bacterial conjunctivitis is the second most common cause of infectious conjunctivitis, with most uncomplicated cases resolving in 1 to 2 weeks. Mattering and adherence of the eyelids on waking, lack of itching, and absence of a history of conjunctivitis are the strongest factors associated with bacterial conjunctivitis. Topical antibiotics decrease the duration of bacterial conjunctivitis and allow earlier return to school or work. Conjunctivitis secondary to sexually transmitted diseases such as chlamydia and gonorrhea requires systemic treatment in addition to topical antibiotic therapy. Allergic conjunctivitis is encountered in up to 40% of the population, but only a small proportion of these individuals seek medical help; itching is the most consistent sign in allergic conjunctivitis, and treatment consists of topical antihistamines and mast cell inhibitors. CONCLUSIONS AND RELEVANCE The majority of cases in bacterial conjunctivitis are self-limiting and no treatment is necessary in uncomplicated cases. However, conjunctivitis caused by gonorrhea or chlamydia and conjunctivitis in contact lens wearers should be treated with antibiotics. Treatment for viral conjunctivitis is supportive. Treatment with antihistamines and mast cell stabilizers alleviates the symptoms of allergic conjunctivitis.
This paper references
10.1001/archopht.1982.01030040253009
Laboratory studies in acute conjunctivitis.
S. Stenson (1982)
10.3126/nepjoph.v3i2.5271
Ocular manifestations in herpes zoster ophthalmicus.
L. Puri (2011)
10.3928/01913913-20081101-07
A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis.
D. Granet (2008)
10.1111/j.1755-3768.1993.tb04983.x
Acute conjunctivitis
I. Hørven (1993)
10.1177/112067219900900403
Treatment of Acute Bacterial Conjunctivitis with Topical Lomefloxacin 0.3% Compared to Topical Ofloxacin 0.3%
K. Tabbara (1999)
A DOUBLE-BLIND DOUBLE-DUMMY COMPARISON OF TOPICAL LOMEFLOXACIN 0.3% TWICE DAILY WITH TOPICAL GENTAMICIN 0.3% FOUR TIMES DAILY IN THE TREATMENT OF ACUT E BACTERIAL CONJUNCTIVITIS
J. A. Montero (1998)
10.1016/S0002-9394(02)02094-9
Azithromycin vs doxycycline in the treatment of inclusion conjunctivitis.
D. Katušić (2003)
10.1016/S0149-2918(00)83044-1
Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model.
S. Butrus (2000)
Micro - biological efficacyof 3 - day treatmentwith azithromycin 1 . 5 % eyedrops for purulent bacterial conjunctivi
F Denis (1997)
10.1002/14651858.cd001211.pub2
Antibiotics versus placebo for acute bacterial conjunctivitis.
A. Sheikh (2006)
Diagnosis andmanagement of dural carotidcavernous sinus fistulas
NR Miller (2007)
10.1136/bjo.84.9.968
Clinical and epidemiological features of acute follicular conjunctivitis with special reference to that caused by herpes simplex virus type 1
E. Uchio (2000)
10.1136/bmj.327.7418.789
Diagnostic impact of signs and symptoms in acute infectious conjunctivitis: systematic literature search
R. Rietveld (2003)
10.1093/jac/23.2.261
Trimethoprim-polymyxin B sulphate ophthalmic ointment versus chloramphenicol ophthalmic ointment in the treatment of bacterial conjunctivitis--a review of four clinical studies. The Trimethoprim-Polymyxin B Sulphate Ophthalmic Ointment Study Group.
(1989)
Evaluation of the clinical and microbiological efficacy of 0.3% ciprofloxacin drops and 0.3% tobramycin drops in the treatment of acute bacterial conjunctivitis
Alves MRKJ (1993)
10.1097/00003226-198706040-00011
Diagnosis and management of herpes simplex stromal keratitis.
K. Wilhelmus (1987)
Chlamydial disease. In: Albert and Jakobiec's Principle and Practice of Ophthalmology
RK Avery (2008)
Topical antibiotics for acute bacterial conjunctivitis: Cochrane systematic review and meta-analysis update.
A. Sheikh (2005)
10.1097/ICU.0b013e3283477cb5
Adenovirus advances: new diagnostic and therapeutic options
H. Kaufman (2011)
Diagnosis andmanagement of dural carotid - cavernous sinus fistulas
NR Miller (2007)
10.2165/11585330-000000000-00000
Treatment of Viral Conjunctivitis with Antiviral Drugs
C. Skevaki (2012)
10.1111/j.1755-3768.2011.02272.x
Management of seasonal allergic conjunctivitis: guide to therapy
B. Bielory (2012)
10.1016/0035-9203(92)90328-A
Causes of conjunctivitis and keratoconjunctivitis in Karachi, Pakistan.
R. Woodland (1992)
10.1038/eye.1987.77
Adult follicular conjunctivitis and neonatal ophthalmia in a Liverpool eye hospital, 1980–1984
S. Harding (1987)
10.1136/BMJ.329.7466.625-B
Predicting bacterial cause in infectious conjunctivitis: Three more questions for “conjunctivitis” may be important
A. Fierz (2004)
10.1136/sti.72.3.203
Epidemiology of genital chlamydial infections in patients with chlamydial conjunctivitis; a retrospective study.
E. J. Postema (1996)
10.1136/bmj.329.7466.625-d
Predicting bacterial cause in infectious conjunctivitis: Authors' reply
Remco P Rietveld (2004)
10.1097/MAJ.0b013e3181637417
Cost Effectiveness of a Point-of-Care Test for Adenoviral Conjunctivitis
Belinda L. Udeh (2008)
10.1038/sj.eye.6701465
External ocular infections due to methicillin-resistant Staphylococcus aureus (MRSA)
V. Shanmuganathan (2005)
10.1093/cid/cir694
Centers for Disease Control and Prevention Sexually Transmitted Disease Treatment Guidelines.
K. Workowski (2011)
10.1016/j.annemergmed.2011.04.006
Sexually transmitted diseases treatment guidelines, 2010.
K. Workowski (2010)
10.1016/j.clinthera.2010.12.004
Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
Bruce E Silverstein (2011)
American College of Cardiology / American Heart Association clinical practice guidelines , part I
RJ Gibbons (2003)
10.1016/S1542-0124(12)70273-2
The ophthalmologic management of acute Stevens-Johnson syndrome.
D. Gregory (2008)
Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness.
C. Owen (2004)
10.1034/J.1600-0420.2003.00079.X
Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis.
V. Yaylalı (2003)
10.1016/j.emc.2007.10.002
Diagnosis and management of the acute red eye.
Ahmed R. Mahmood (2008)
10.1097/ACI.0b013e32834a9676
Epidemiology of allergic conjunctivitis.
N. Rosario (2011)
10.1177/000992289703600801
A Comparison of Ciprofloxacin and Tobramycin in Bacterial Conjunctivtis in Children
R. D. Gross (1997)
Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology
MB McDonald (2009)
10.1097/00003226-200201000-00010
Treatment of Acute Bacterial Conjunctivitis With Topical Netilmicin
V. Papa (2002)
10.1016/J.OPHTHA.2006.06.029
The RPS adeno detector for diagnosing adenoviral conjunctivitis.
R. Sambursky (2006)
10.1097/INF.0b013e3181b99fa2
Efficacy and Safety of Azithromycin 1.5% Eye Drops for Purulent Bacterial Conjunctivitis in Pediatric Patients
D. Brémond-Gignac (2010)
10.1007/BF02848694
Single dose of ketotifen fumarate .025% vs 2 weeks of cromolyn sodium 4% for allergic conjunctivitis
J. Greiner (2002)
10.1159/000027430
Topical Lomefloxacin 0.3% Twice Daily versus Tobramycin 0.3% in Acute Bacterial Conjunctivitis: A Multicenter Double-Blind Phase III Study
P. Gallenga (1999)
Bacterial conjunctivitis.
John W. Epling (2010)
10.1136/bjo.69.5.385
Prevalence of chlamydial eye infection in patients attending an eye clinic, a VD clinic, and in healthy persons.
R. Rönnerstam (1985)
Diagnosis and management of red eye in primary care.
H. Cronau (2010)
10.1016/j.clinthera.2009.03.010
Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
P. Karpecki (2009)
10.2500/aap.2012.33.3525
Allergic conjunctivitis: the evolution of therapeutic options.
L. Bielory (2012)
A comparison of eye problems in primary care and ophthalmology practices.
T. Shields (1991)
10.1093/infdis/160.6.938
A large outbreak of epidemic keratoconjunctivitis: problems in controlling nosocomial spread.
D. Warren (1989)
10.1097/00132980-200512000-00016
Allergic reaction to topical eyedrops.
C. Baudouin (2005)
10.1136/bjo.2006.103556
3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children
I. Cochereau (2007)
10.1016/J.CLINTHERA.2005.04.011
A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
J. Greiner (2005)
10.4135/9781412950558.n72
[Centers for Disease Control and Prevention (CDC)].
P. Wolkenstein (2000)
Diagnosis and management of dural carotid-cavernous sinus fistulas. Neurosurg Focus
NR Miller (2013)
Chlamydial disease
RK Avery (2008)
10.1016/S0161-6420(89)32749-7
Epidemiology and diagnosis of acute conjunctivitis at an inner-city hospital.
C. Fitch (1989)
10.1161/01.CIR.0000063682.20730.A5
American College of Cardiology/American Heart Association clinical practice guidelines: Part I: where do they come from?
R. Gibbons (2003)
10.1136/bjo.87.8.1004
A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis
D. Hwang (2003)
10.1016/S0161-6420(02)01894-8
A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
I. Schwab (2003)
10.3171/FOC-07/11/E13
Diagnosis and management of dural carotid-cavernous sinus fistulas.
N. Miller (2007)
10.1111/J.1600-0420.1999.TB01174.X
Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model.
J. Deschênes (1999)
10.3949/CCJM.75.7.507
Bacterial conjunctivitis: a review for internists.
A. Tarabishy (2008)
10.1016/S0008-4182(02)80114-4
Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops.
W. B. Jackson (2002)
10.1016/S0002-9394(14)70640-3
Possible consequences of shaking hands with your patients with epidemic keratoconjunctivitis.
M. Azar (1996)
10.1016/B978-1-4160-4919-7.50064-5
Disorders of the conjunctiva and limbus
F. Ferri (2009)
10.4269/AJTMH.2003.69.24
The global elimination of blinding trachoma: progress and promise.
J. Kumaresan (2003)
10.1016/j.ajo.2008.01.019
Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial.
M. Abelson (2008)
10.1161/01.CIR.0000145143.19711.78
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association
J. Newburger (2004)
Tolerancia y eficacia de la tobramicina tópica vs cloranfenicol en el tratamiento de las conjunctivitis bacterianas
Valentín Huerva (1991)
10.1177/112067210801800602
Microbiologic Efficacy of 3-day Treatment with Azithromycin 1.5% Eyedrops for Purulent Bacterial Conjunctivitis
F. Denis (2008)
10.1016/J.AJO.2007.03.032
Spectrum of eye disease caused by methicillin-resistant Staphylococcus aureus.
Julie Freidlin (2007)
10.1097/ICO.0b013e31823cbe6a
Practice Patterns and Opinions in the Management of Recurrent or Chronic Herpes Zoster Ophthalmicus
A. Sy (2012)
10.1185/03007990902837919
Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis.
M. Tepedino (2009)
10.1111/j.1600-0420.2007.01006.x
Acute bacterial conjunctivitis
G. Høvding (2008)
10.1007/BF02854842
Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: a multicenter comparison in patients with seasonal allergic conjunctivitis
Peter C. Donshik (2000)
Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis.
H. Leibowitz (1991)
10.3760/CMA.J.ISSN.0412-4081.2010.06.011
[Comparative research of the efficacy of the gatifloxacin and levofloxacin for bacterial conjunctivitis in human eyes].
L. Gong (2010)
10.1185/03007990903038269
Acute conjunctivitis: truth and misconceptions
T. O'brien (2009)
10.1177/112067210901900101
Clinical and Microbiological Efficacy of Levofloxacin Administered three Times a Day for the Treatment of Bacterial Conjunctivitis
J. Szaflik (2009)
10.1016/j.ophtha.2009.05.014
Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
M. Mcdonald (2009)
10.1097/00006454-198809000-00005
Comparison of three topical antimicrobials for acute bacterial conjunctivitis.
J. Lohr (1988)
10.1016/0002-9394(57)90152-6
Clinical trial of erythromycin ophthalmic ointment.
John W. Hallett (1957)
10.1056/NEJM200008033430507
The red eye.
H. Leibowitz (2000)
10.1016/S0149-2918(03)80200-X
A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model.
J. Greiner (2003)
10.3928/01913913-20070301-03
Exclusion of students with conjunctivitis from school: policies of state departments of health.
Christina Ohnsman (2007)
10.1136/bmj.38128.631319.AE
Predicting bacterial cause in infectious conjunctivitis: cohort study on informativeness of combinations of signs and symptoms
R. Rietveld (2004)
10.1186/1471-2415-9-13
Estimate of the direct and indirect annual cost of bacterial conjunctivitis in the United States
Andrew F Smith (2009)
[Clinical investigation of 0.3% levofloxacin eyedrops on the treatment of cases with acute bacterial conjunctivitis and bacterial keratitis].
M. Zhang (2000)
10.1002/jmv.1890250306
Spread of acute hemorrhagic conjunctivitis due to enterovirus‐70: Effect of air temperature and relative humidity on virus survival on fomites
S. Sattar (1988)



This paper is referenced by
10.1007/978-3-319-72063-0
Staphylococcus aureus
Д. Іванова (2017)
10.1089/jop.2014.0040
Gatifloxacin 0.5% administered twice daily for the treatment of acute bacterial conjunctivitis in patients one year of age or older.
Warren H Heller (2014)
10.2147/OPTH.S236571
A Review of the Differential Diagnosis of Acute Infectious Conjunctivitis: Implications for Treatment and Management
Elizabeth Yeu (2020)
Kira L. SegalEdward C. LaiChristopher E. Starr
Kira L. Segal (2014)
10.1007/s10792-017-0678-0
An evidence-based medicine audit of the ophthalmic emergency services unit of King Abdulaziz University Hospital (KAUH)
Adel H. Alsuhaibani (2017)
10.15242/heaig.er0917215
A Study on the Etiologic Agents of Bacterial Eye Infections in Khartoum State
Nuha M. Elhage (2018)
10.1038/srep23858
Ambient air pollution, weather changes, and outpatient visits for allergic conjunctivitis: A retrospective registry study
Jiaxu Hong (2016)
10.3390/nano10061191
Niosomal Drug Delivery Systems for Ocular Disease—Recent Advances and Future Prospects
Saliha Durak (2020)
10.1186/s12879-019-4232-8
An outbreak of epidemic keratoconjunctivitis caused by human adenovirus type 8 in primary school, southwest China
Duo Li (2019)
10.5812/jjm.92549
Transmission Rates of Chlamydia trachomatis and Neisseria gonorrhoeae Infections from Pregnant Women to Newborns, Tehran, Iran
A. Esteghamati (2020)
10.5772/INTECHOPEN.76039
Chitosan: A Good Candidate for Sustained Release Ocular Drug Delivery Systems
L. Popa (2018)
10.1177/1040638716642268
Diagnostic investigation of new disease syndromes in farmed Australian saltwater crocodiles (Crocodylus porosus) reveals associations with herpesviral infection
C. Shilton (2016)
10.1016/j.clae.2020.07.002
Influence of the COVID-19 pandemic on contact lens wear in Spain
D. García-Ayuso (2020)
10.1089/JOP.2014.0040
Gatifloxacin 0.5% administered twice daily for the treatment of acute bacterial conjunctivitis in patients one year of age or older.
HellerWarren (2014)
10.1016/B978-0-7020-6285-8.00016-2
16 – Conjunctivitis, Keratitis and Infections of Periorbital Structures
M. Drancourt (2017)
10.1089/JOP.2017.0056
Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial.
Baiza-DuránLeopoldo (2018)
10.1016/j.clae.2020.03.012
The COVID-19 pandemic: Important considerations for contact lens practitioners
L. Jones (2020)
10.36303/sagp.2020.1.1.0010
An overview of allergic and bacterial conjunctivitis
Natalie Schellack (2020)
10.1001/jamaophthalmol.2017.6189
Chronic Follicular Conjunctivitis in a Middle-aged Woman.
Nicholas P Hadjokas (2018)
10.20944/PREPRINTS201901.0128.V2
Conjunctivitis and Exposure to Ambient Ozone
Mieczyslaw Szyszkowicz (2019)
10.3390/microorganisms7090351
Disparate Entry of Adenoviruses Dictates Differential Innate Immune Responses on the Ocular Surface
M. R. Pennington (2019)
10.1177/1357633X18793031
Treating pediatric conjunctivitis without an exam: An evaluation of outcomes and antibiotic usage
Kristine S Penza (2018)
10.14260/jemds/2014/3746
A PROSPECTIVE OBSERVATIONAL STUDY OF THE COURSE OF CLINICAL INFECTIVE CONJUNCTIVITIS & ANALYSIS OF THE SEQUEL OF ITS CORNEAL INVOLVEMENT
M. Vasudevan (2014)
10.1007/978-981-13-9871-1_3
Emergence and Spread of Multidrug Resistance in Ocular Bacterial Pathogens: A Current Update
Sarim Ahmad (2019)
10.4102/safp.v60i6.4933
A "site" for sore eyes
G. Muntingh (2018)
10.1186/s12886-015-0078-z
Bacterial isolates and their antimicrobial susceptibility pattern among patients with external ocular infections at Borumeda hospital, Northeast Ethiopia
B. Shiferaw (2015)
10.3390/pathogens7010009
The Pathogenesis of Staphylococcus aureus Eye Infections
R. O'Callaghan (2018)
Bacteriology and Antimicrobial Susceptibility Patterns of Childhood Acute Bacterial Conjunctivitis in Western Greece
Maria-Zoi Oikonomakou (2019)
10.9734/JAMCS/2019/V31I330113
Stochastic Optimal Control Model of Haemorrhagic Conjunctivitis Disease
Sacrifice Nana-Kyere (2019)
10.1097/ICO.0000000000000562
Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model
Eugene B. McLaurin (2015)
10.1097/ICU.0000000000000485
Adenoviral keratitis: a review of the epidemiology, pathophysiology, clinical features, diagnosis, and management
Amro A Omari (2018)
10.23886/ejki.5.7605.65-71
Viral Conjunctivitis: Diagnosis and Therapy in Primary Health Care
R. Sitompul (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar